A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)

Overview of attention for article published in Journal of Neurodevelopmental Disorders, November 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#3 of 482)
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 27 news outlets

twitter: 8 X users

Citations

dimensions_citation: 22 Dimensions

Readers on

mendeley: 47 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 8 X posts from 8 X users, with an upper bound of 116,303 followers.

“…significant improvement was demonstrated in patients.” ⛓️https://t.co/UWq6N3xXUX

24 Jan 2023

Reply Repost Favourite

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX) https://t.co/OFJyWCoMQA

15 Jan 2023

Reply Repost Favourite

RCT in patients: ZYN002 #cannabidiol #CBD #transdermal gel in children and adolescents with #fragile X syn… https://t.co/elm5Er4U37

08 Dec 2022

Reply Repost Favourite

RT @Spectrum: A cannabinoid gel called ZYN002, made by Zynerba to treat fragile X syndrome, improves social avoidance behavior in clinical…

07 Dec 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.